Skin & Regeneration
Rejuran vs. Juvelook: What the Available Evidence Can Compare
Rejuran and Juvelook are product names, not ingredients. The cited under-eye cohort examined one Juvelook 50 mg formulation. To understand what the study covers, check the formulation, the people and area studied, the injection schedule, and what is assessed before treatment. This single cohort cannot rank the products or establish equivalence. Its composition figures are not a patient dose, and three monthly injections describe a study schedule rather than a general recommendation. The authors call for longer research on durability and long-term safety around the eyes. The Korean Dermatological Association’s general filler checks do not establish absolute contraindications for either product.
- The studied 50 mg formulation contained 42.5 mg of PDLLA and 7.5 mg of non-cross-linked HA. Those figures describe that formulation alone.
- Three injections at one-month intervals were used in the study; they are not a recommended schedule for everyone. Longer-term safety needs further study.
- The conditions and medicines checked before general filler procedures are not product-specific lists of absolute contraindications.
- Exclusions from the under-eye cohort cannot be applied to every patient or body area.
The study describes one 50 mg formulation. Its ingredients cannot be assumed to describe another formulation sold under the same name or the other product in this article. The study also offers no head-to-head ranking.
What the study product contained
In a prospective cohort published in Aesthetic Plastic Surgery, researchers followed 15 Asian women who received injections in the tear trough and under-eye area. The 50 mg study formulation contained 42.5 mg of poly-D,L-lactic acid (PDLLA) and 7.5 mg of non-cross-linked hyaluronic acid (HA). Those numbers describe its contents, not an amount to inject into one person.
Composition applies to one formulation
The ingredient description is specific to the 50 mg formulation. It does not establish the contents of other formulations under the same product name or of the other product discussed here.
The study schedule is not a general recommendation
The cohort used three injections, one month apart. This was its research schedule, not a recommended regimen. The authors call for longer studies of durability and long-term safety around the eyes; the follow-up period does not establish a maintenance interval. The full-text Results report mild under-eye swelling in most participants for a few hours to two days and temporary injection-site bruising in two participants; no other adverse events were reported. The paper also notes a potential risk of nodules and granulomas with biostimulator injectables in the thin under-eye area. This class-level concern was not reported in the small cohort.
What is checked before general filler procedures
Before general filler procedures, the Korean Dermatological Association describes checking for severe or chronic systemic disease, allergic disease, keloids, autoimmune disease, connective tissue disease, and viral disease. It also lists aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. These are general filler checks, not absolute contraindications for either product. Discuss medication changes with the prescribing and treating clinicians.
The Korean Association for Laser, Dermatology and Trichology lists area-specific volume adjustment and injection-plane (tissue-depth) understanding in the third session of a 2025 education program. That training agenda sets no universal injection volume or depth for an individual.
How to read the under-eye study’s exclusions
The under-eye cohort excluded people with marked eyelid laxity, marked orbital fat prolapse, or a previous permanent filler injection in the same area. Its stated exclusions are not exhaustive and do not become absolute contraindications for every patient or other injection sites.
References
- “Hybrid Biostimulator and Hyaluronic Acid Injectable for Tear Trough Rejuvenation.” Aesthetic Plastic Surgery, Springer Nature. https://link.springer.com/article/10.1007/s00266-026-05817-z
- “보툴리눔독소, 필러” (in Korean). Korean Dermatological Association. https://www.derma.or.kr/new/general/treatment.php?mod=document&uid=1118
- “2025 제1회 미용의학통합교육과정 (2/9~4/20)” (in Korean). Korean Association for Laser, Dermatology and Trichology. https://kaldat.co.kr/seminar/previous/44?page=1&search_type=title
Frequently asked questions
Do the two products contain the same ingredients?
This one under-eye cohort cannot establish that their ingredients are either the same or different. It identifies the studied 50 mg formulation as containing 42.5 mg of poly-D,L-lactic acid (PDLLA) and 7.5 mg of non-cross-linked hyaluronic acid (HA). The other product's composition needs separate, product-specific evidence.
Are three injections one month apart required?
No. Three injections at one-month intervals were the schedule used in a prospective under-eye cohort of 15 Asian women. That research schedule does not set the number or spacing of injections for an individual.
Should I stop aspirin or anti-inflammatory medicine beforehand?
The Korean Dermatological Association says aspirin and nonsteroidal anti-inflammatory drug (NSAID) use should be checked before a general filler procedure. It does not say to stop them on your own. Discuss any medication change with both the prescribing clinician and the clinician assessing the injection.
What determines eligibility for under-eye injections?
The cited under-eye cohort excluded people with marked eyelid laxity, marked orbital fat prolapse, or a history of permanent filler injection in that area. These are study-specific exclusions, not a complete list or universal contraindications. Individual suitability requires clinical assessment.